MET and neoplasm: Afatinib resistant tumor cell killing by [ERBB3 + c-KIT + c-MET] knock down was significantly, though only partially i.e. ∼70% reduction, reduced by knock down of eIF2α, CD95 or Beclin1 (Figure 4A, p < 0.05).